Malaria drug tested to boost lung cancer treatment
NCT ID NCT00977470
Summary
This study is testing whether adding hydroxychloroquine (an FDA-approved malaria drug) to the cancer drug erlotinib helps treat advanced non-small cell lung cancer with specific genetic mutations. Researchers want to see if this combination can delay or prevent the cancer from becoming resistant to treatment. The study involves 76 participants who will receive either erlotinib alone or erlotinib plus hydroxychloroquine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Stanford Cancer Institute
Stanford, California, 94305, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
Yale Cancer Center
New Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.